Arvinas and Pfizer Announce Phase 3 VERITAC-2 Trial Results Showing Vepdegestrant Improves Progression-Free Survival in ESR1-Mutant Breast Cancer Patients

Arvinas and Pfizer announced positive Phase 3 trial results for vepdegestrant in metastatic breast cancer patients with ESR1 mutations, demonstrating a 2.9-month improvement in median progression-free survival compared to fulvestrant, and reducing the risk of disease progression or death by 43%. The VERITAC-2 trial, involving 624 participants, showed a statistically significant PFS benefit for those with ESR1 mutations and a favorable safety profile for vepdegestrant, which the companies plan to submit for FDA approval in late 2025, despite the trial not reaching statistical significance in the intent-to-treat population.

Analysis

Arvinas, Inc. (ARVN) and Pfizer, Inc. (PFE) announced mixed Phase 3 VERITAC-2 trial results for vepdegestrant in ER+/HER2- advanced or metastatic breast cancer. The drug demonstrated a statistically significant and clinically meaningful 2.9-month improvement in median progression-free survival (PFS) (5.0 months vs. 2.1 months) and a 43% reduction in risk of disease progression or death (HR=0.57, p<0.001) compared to fulvestrant specifically in patients with ESR1 mutations. Vepdegestrant also showed a favorable safety profile, with low rates of gastrointestinal side effects and few treatment discontinuations (2.9%). However, the trial did not achieve statistical significance for PFS improvement in the broader intent-to-treat (ITT) population (median PFS 3.7 months for vepdegestrant vs. 3.6 months for fulvestrant, HR=0.83, p=0.07), which is a significant concern for wider applicability. Overall survival data remains immature. The companies plan an FDA New Drug Application submission in late 2025, targeting the ESR1-mutated population, which represents approximately 40% of patients in the second-line setting. Insider activity for ARVN shows exclusively sales over the past six months, with key executives selling shares. Institutional holdings data reveals significant divestment by several large funds in the recent quarter, including ECOR1 Capital and Bellevue Group AG, although Alyeska Investment Group initiated a substantial new position. Analyst ratings remain positive with three recent buy ratings, and the median price target is $16.0, though targets vary widely from $11.0 to $26.0. The combination of strong subgroup efficacy, a good safety profile, and high-profile publication is offset by the ITT population miss and concerning insider/institutional selling patterns, creating a nuanced outlook.

Key Decisions for Investors

• Investors should carefully weigh the strong efficacy in the ESR1-mutated subgroup against the failure to meet the primary endpoint in the broader intent-to-treat population, as this could impact the drug's market potential and regulatory pathway.
• Monitor Arvinas' planned FDA submission in H2 2025 and subsequent regulatory feedback, particularly concerning the ITT population results and the potential for a label restricted to ESR1-mutated patients.
• The consistent insider sales by Arvinas executives and significant institutional selling warrant caution and further due diligence regarding internal valuation perceptions and potential risks not fully captured by the positive subgroup data.
• Consider the immature overall survival data as a key uncertainty; future updates on OS will be critical in assessing the long-term clinical and commercial viability of vepdegestrant.